title: Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature.
abstract: Persistent hiccups have been reported to occur occasionally during rehabilitation hospitalizations. Hiccups can interfere with patient participation and progress, and this can lengthen and complicate the rehabilitation hospitalization. Chlorpromazine, the only Food and Drug Administration-approved agent specifically indicated for hiccups, is often chosen as a first-line treatment. However, chlorpromazine does not always provide favorable results. The intent of this paper is to (1) review hiccups and implications of persistent hiccups in the rehabilitation setting, (2) provide additional evidence that chlorpromazine is often not the best treatment choice for hiccups in rehabilitative patients, (3) report the effectiveness and favorable tolerability of modest doses of gabapentin in a small case series of three patients, and (4) review potentially effective treatment approaches for hiccups.
authors: Department of Physical Medicine and Rehabilitation, Scott and White Clinic, Scott, Sherwood, and Brindley Foundation, Temple, Texas 76508, USA.
authors: John A
authors: JA
authors: Schuchmann
authors: Barry A
authors: BA
authors: Browne
mesh_terms: D000368:Aged; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use; D002544:Cerebral Infarction / Q000150:complications; D002746:Chlorpromazine / Q000627:therapeutic use*; D002908:Chronic Disease; D000075202:Contraindications; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D000077206:Gabapentin; D006470:Hemorrhage / Q000150:complications; D006606:Hiccup / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D012047:Rehabilitation Centers; D012307:Risk Factors; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000588:Amines; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D018491:Dopamine Agonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D002746:Chlorpromazine